Arbutus Biopharma Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $ABUS in the last 7 days.
No SEC Form 4 filings for $ABUS in the last 30 days.
See all $ABUS insider activity →Arbutus Biopharma (ABUS) launched a $230M stock repurchase tender offer, following strong share price gains. The company trades at a P/E of 6.7x, lower than US equities and biotech peers, but higher than its estimated fair P/E of 1.3x. Analysts forecast declining revenue and earnings, with risks tied to trial results and licensing progress.
Arbutus Biopharma (ABUS) shares rose 6% as Moderna (MRNA) is set to make a $950M upfront payment by July 8 under a $2.25B settlement, with ABUS receiving ~$179M. The dispute involved patented lipid nanoparticle technology used in Moderna's COVID-19 vaccine. ABUS also progresses its hepatitis B drug, imdusiran, with FDA Fast Track designation. Analysts rate ABUS a 'buy' with a $5.14 avg. price target.
Arbutus Biopharma (Nasdaq: ABUS) launched a US$230 million modified Dutch Auction tender offer for up to 23.2% of its shares at US$5.00–US$5.75 per share. The offer, starting August 24, 2026, expires September 29, 2026, unless extended. The company obtained exemptive relief from U.S. and Canadian regulators. The purchase price will be determined based on the tendered shares and prices.
Recent ABUS coverage spans corporate actions and market movers.
The buyback signals confidence and may provide short‑term price support.
Potential cash infusion could improve balance sheet and enable shareholder returns.
The tender offer creates immediate buy‑side pressure and may depress the share price if the purchase price is set below current levels.
The tender offer provides a cash‑backed floor and a clear upside target, likely supporting further short‑term buying.
The settlement cash and planned $230M buyback improve liquidity and support upside, while ongoing litigation adds upside risk.
alphai scores every news story that mentions ABUS with an AI model for sentiment and relevance, and aggregates insider trades from Arbutus Biopharma Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Arbutus Biopharma (ABUS) launched a $230M stock repurchase tender offer, following strong share price gains. The company trades at a P/E of 6.7x, lower than US equities and biotech peers, but higher than its estimated fair P/E of 1.3x. Analysts forecast declining revenue and earnings, with risks tied to trial results and licensing progress.
2 min readArbutus Biopharma (ABUS) shares rose 6% as Moderna (MRNA) is set to make a $950M upfront payment by July 8 under a $2.25B settlement, with ABUS receiving ~$179M. The dispute involved patented lipid nanoparticle technology used in Moderna's COVID-19 vaccine. ABUS also progresses its hepatitis B drug, imdusiran, with FDA Fast Track designation. Analysts rate ABUS a 'buy' with a $5.14 avg. price target.
2 min readArbutus Biopharma (Nasdaq: ABUS) launched a US$230 million modified Dutch Auction tender offer for up to 23.2% of its shares at US$5.00–US$5.75 per share. The offer, starting August 24, 2026, expires September 29, 2026, unless extended. The company obtained exemptive relief from U.S. and Canadian regulators. The purchase price will be determined based on the tendered shares and prices.
2 min readArbutus Biopharma (ABUS) stock rose 10.86% after launching a $230M tender offer. The company reported Q2 revenue of $1.0M, negative EBIT, and strong balance sheet metrics, including zero net debt and $271M working capital. Analysts note bullish technical trends and a target range of $6.00–$7.00 over 6–12 months.
2 min readArbutus Biopharma (ABUS) stock rose 7.13% on optimism about its hepatitis B pipeline and a $950M settlement with Moderna, which provided $178M in cash. The company has $92.6M in cash and minimal debt, plans a $230M share buyback, and received FDA Fast Track designation for its RNAi therapy imdusiran (AB-729). Q2 2026 revenue was $1.0M with a net loss of $5.1M.
3 min readArbutus Biopharma's board authorized a share buyback plan on August 21, 2026. The company's stock has seen a 5-day change of $5.210, with a 9.22% increase over the past year.
1 min readArbutus Biopharma (NasdaqGS:ABUS) announced a $230 million share repurchase program, buying shares at $5.00 to $5.75 each. The offer, funded by cash on hand, is valid until September 29, 2026.
1 min readArbutus Biopharma (ABUS) stock rose 9.8% after announcing a $230M share repurchase plan at $5.00-$5.75 per share, funded by cash from a Moderna settlement. The buyback is set to start August 24, 2026. The company also has ongoing patent disputes with Pfizer and BioNTech. The broader market showed mild gains, but did not significantly impact ABUS's surge.
2 min readArbutus Biopharma (ABUS) shares rose 10% after announcing a $230M share repurchase plan at $5-$5.75 per share, funded by existing cash. Q2 revenue was $1.01M, exceeding estimates. The company also filed lawsuits against Pfizer and BioNTech over LNP technology patents. ABUS has gained 33% over the past year.
2 min readArbutus Biopharma (Nasdaq: ABUS) plans to repurchase up to $230 million of its common shares through a modified Dutch Auction tender offer. The offer will run from August 24, 2026, to September 29, 2026, at a price between $5.00 and $5.75 per share. The company will use cash on hand to fund the repurchase.
2 min read
